Atossa Genetics (NASDAQ: ATOS) reported Q3 EPS of ($0.15), versus ($0.13) reported last year. Revenue for the quarter came in at $772.2 thousand, versus $3.4 thousand reported last year.

Announced today that the National Cancer Institute, Division of Cancer Prevention, has approved a Letter of Intent submitted by a member of the Consortia for Cancer Prevention Clinical Trials Program for the study of Afimoxifene Gel in women with DCIS. The Consortia includes five major medical research centers: the University of Arizona, Northwestern University, Mayo Clinic Foundation, M. D. Anderson Cancer Center and the University of Wisconsin.

For earnings history and earnings-related data on Atossa Genetics (ATOS) click here.